尊龙凯时
About us
尊龙凯时:Our Values
尊龙凯时:Development Milestone
Products
尊龙凯时:Product List for API
尊龙凯时:Recommended API
尊龙凯时:Product list for Chemicals and Intermediates
Product list for Chemicals and Intermediates
News
尊龙凯时:Contract Manufacturing
尊龙凯时:API and Pharmaceutical Intermediates
尊龙凯时:OTC and Generics
尊龙凯时:Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
Contact Us
About us
News
Investor Relation
Products
尊龙凯时:Contract Manufacturing
尊龙凯时:Contact Us
Investor Relation
Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
INVESTORS SERVICE
Announcement on Calcium Gluconate Injection Passing the Generics Consistency Evaluation
2024-11-05
Announcement on Pentazocine Having Obtained the Notification of Approval of Marketing Application for Chemical Substance Drugs
2024-11-04
Announcement on Drugs of Wholly-owned Subsidiary Passing the Generics Consistency Evaluation
2024-11-04
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024
2024-11-01
Change of Branch Share Registrar and Transfer Office in Hong Kong
2024-10-29
Announcement on Absorption and Merger of Wholly-owned Subsidiary
2024-10-29
Renewal of Continuing Connected Transactions and Related Party Transaction and Entering into of Continuing Connected Transactions
2024-10-29
Overseas Regulatory Announcement-Announcement on Having Obtained FDA approval of Abbreviated New Drug Application (ANDA)
2024-10-28
Overseas regulatory announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
2024-10-28
Articles of Association
2024-10-25
<
1
2
3
4
5
6
7
...
>